Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England ...

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM ...

Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with ...

Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients ...

AI Isn’t Killing Marketing Accountability, It’s Exposing Who Never Had It

A bookstore's AI-altered ad exposed a gap most marketing teams haven't fixed – nobody owns what AI changes after approval.

Ollama's Qwen3-VL introduces the most powerful vision language model - here's how it works

AI is advancing at a rapid rate, and Ollama claims its Qwen3-VL is the most powerful vision language model yet. Here's what ...

Programming Memes for Coding Geeks

The world we live in is built on computer power.From the smartphones that so many of us can't put down to the global banking ...
CNBC

5 Things to Know

5 Things to Know is CNBC's Morning Squawk newsletter, a before-the-bell briefing on the most important news, trends and analysis that investors need to start their trading day. Subscribe here to ...